Floatz logo

NANOPARTICLE EPIRUBICIN

Neoplasm

NanoCarrier Co., Ltd.OtherPhase 1/2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

928 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
VITAMIN D
Tanta University
Phase 4BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

NANOPARTICLE EPIRUBICIN is also rated in:

sarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
soft tissue sarcomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →